Ascentage Pharma Group International
HKEX:6855.HK
Overview | Financials
Company Name | Ascentage Pharma Group International |
Symbol | 6855.HK |
Currency | HKD |
Price | 44.2 |
Market Cap | 13,855,570,911 |
Dividend Yield | 0% |
52-week-range | 15.42 - 48.85 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Dajun Yang M.D., Ph.D. |
Website | https://www.ascentagepharma.com |
An error occurred while fetching data.
About Ascentage Pharma Group International
Ascentage Pharma Group International, a clinical-stage biotechnology company, engages in developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in the United States and Mainland China. Its primary product HQP1351, a BCR-ABL inhibitor targeting BCR-ABL mutants, including those with the T315I mutation, as well as for patients
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD